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Background: Chemoradiation therapy (CRT) has been widely used for unresectable esophageal squamous cell
carcinoma (ESCC) patients. However, many patients develop local recurrence after CRT. In this study, we hypothesized
that the immunotherapy by peptide vaccine may be effective for the eradication of minimal residual cancer cells after
CRT. This study was conducted as a phase I clinical trial of multiple-peptide vaccine therapy combined with CRT on
patients with unresectable ESCC.
Patients and methods: HLA-A*2402 positive 11 unresectable chemo-naïve ESCC patients were treated by
HLA-A*2402-restricted multi-peptide vaccine combined with CRT. The peptide vaccine included the 5 peptides as
follows; TTK protein kinase (TTK), up-regulated lung cancer 10 (URLC10), insulin-like growth factor–II mRNA binding
protein 3 (KOC1), vascular endothelial growth factor receptor 1 (VEGFR1) and 2 (VEGFR2). CRT consisted of radiotherapy
(60 Gy) with concurrent cisplatin (40 mg/m2) and 5-fluorouracil (400 mg/m2). Peptide vaccines mixed with incomplete
Freund’s adjuvant were injected subcutaneously once a week on at least 8 occasions combined with CRT.
Results: Vaccination with CRT therapy was well-tolerated, and no severe adverse effects were observed. In the case of
grade 3 toxicities, leucopenia, neutropenia, anemia and thrombocutopenia occurred in 54.5%, 27.3%, 27.3% and 9.1%
of patients, respectively. Grade 1 local skin reactions in the injection sites of vaccination were observed in 81.8% of
patients. The expressions of HLA class I, URLC10, TTK, KOC1, VEGFR1 and VEGFR2 antigens were observed in the tumor
tissues of all patients. All patients showed peptide-specific cytotoxic T lymphocytes responses in at least one of the 5
kinds of peptide antigens during the vaccination. Six cases of complete response (CR) and 5 cases of progressive
disease (PD) were observed after the 8th vaccination. The 4 CR patients who continued the peptide vaccination
experienced long consistent CR for 2.0, 2.9 4.5 and 4.6 years.
Conclusions: A combination therapy of multi-peptide vaccine with CRT can successfully be performed with
satisfactory levels of safety, and application of this combination therapy may be an effective treatment for patients
with unresectable ESCC.
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Esophageal squamous cell carcinoma (ESCC) is a highly
malignant disease, especially in Asia. In Japan, the
number of deaths attributable to ESCC has been slowly
increasing, and 11,345 people died in 2011 [1]. Recent
developments in surgical techniques and postoperative
management including chemotherapy and fractionized
radiation therapy, have contributed to improvements
in the surgical outcome [2,3]. Chemoradiation therapy
(CRT) has been used in Japan since 1990, especially for
unresectable ESCC patients with locally advanced disease
and/or distant metastasis, or for those who were not fit to
undergo surgery [3]. However, it has been reported that
many patients develop local recurrence soon after CRT
[4-8]. This recurrence is due to the difficulty in making a
precise clinical assessment of CRT on the treated cancer
tissues. Viable cancer cells are thought to remain at the
primary site in the majority of patients even if clinical
complete response (CR) is accomplished. Although salvage
esophagectomy was recommended in recurrent patients
after CRT, high incidences of mortality and radiation-
related post-operative complications, such as pneumonitis
and cardiomyositis, have been reported [9]. Therefore, the
development of a new approach for residual cancer cells
after CRT is necessary to improve the prognosis of
patients with unresectable ESCC.
A multimodality approach for ESCC is preferred in
order to improve prognosis of CRT, and immunotherapy
can be viewed as one rational approach for combination
therapy with CRT. Recent studies have suggested that
local irradiation elicits immunomodulatory effects and
induces tumor-specific immune responses [10-14]. Fur-
thermore, fluorouracil (5-FU) and cisplatin (CDDP), the
standard agents for the treatment of ESCC, may immuno-
modulate the anti-tumor immunological response through
the down regulation of immunosuppressive regulatory T
cells and/ or increase the expression of MHC molecules
[15-17]. In this study, we hypothesized that the CRT may
act immunogenically, and immunotherapy with peptide
vaccine may be effective for the eradication of residual
cancer cells after CRT.
By using cDNA microarray technology coupled with
laser microdisection, we identified novel HLA-A*2402
(which is the most common HLA-A allele in the Japanese
population) - restricted epitope peptides as targets for
cancer vaccination [18-21]. In particular, it has been dem-
onstrated that TTK protein kinase (TTK), up-regulated
lung cancer 10 (URLC10) and insulin-like growth factor–
II mRNA binding protein 3 (KOC1) are promising targets
for cancer vaccination in advanced ESCC patients [22,23].
Furthermore, to overcome the inhibition of the antitumor
effects of cytotoxic T lymphocytes (CTL), which occur
due to the down regulation of human leukocyte antigen
(HLA), we focused on the peptide vaccine targeting thevascular endothelial growth factor receptor 1 (VEGFR1)
and 2 (VEGFR2). It has been reported that CTLs were
strongly induced by these peptides in various cancer
patients [24].
In this study, we attempted a phase I clinical trial of
multi-peptide vaccines in combination with CRT for unre-
sectable ESCC patients. We selected 5 peptide vaccines
(TTK, URLC10, KOC1, VEGFR1 and VEGFR2) to over-
come the immune-escape mechanisms and increase the
therapeutic potential of the cancer vaccine. The primary
endpoint of this study is an evaluation of the safety factors,
and secondary endpoints are estimation of the immune
responses and clinical responses.
Materials and methods
Study design and treatment protocol
This study was a phase I clinical trial of dose-escalated
multiple-peptide vaccine (TTK, URLC10, KOC1, VEGFR1
and VEGFR2) combined with CRT. Each peptide vaccine
was mixed with incomplete Freund’s adjuvant (IFA)
(Montanide ISA 51; Seppic, Paris, France) separately,
and was injected subcutaneously in 11 unresectable
ESCC patients with stage II (3 cases), stage III (4 cases)
or stage IV (4 cases). All patients were chemo-naïve.
Treatment consisted of 2 courses of CDDP 40 mg/m2
(day1, 8) and 5-FU 400 mg/m2/day (days 1-5, 8-12)
combined with concurrent radiotherapy of 60 Gy in 30
fractions as described previously [7]. During the break
period of chemotherapy, 5 kinds of peptide vaccines
were administered once every week, a total 8 times
(Additional file 1: Figure S1). Dose escalation was per-
formed in 3 patients’ cohort with dose of 0.5 mg, 1 mg
and 3 mg for each peptide. For the imaging analysis,
computed tomography (CT) scan and endoscopy were
performed at pre-treatment period and every 2 ~ 3 months
after the vaccination, and every measureable legion was
evaluated by RECIST. CR patients additionally received
5 kinds of peptide vaccine, once every 2 weeks for 1 year
and then once a month until changes to the progressive
disease (PD) were observed. The primary endpoint of this
trial was to evaluate the safety of this therapy. The second-
ary endpoints were to investigate the immunological re-
sponse and clinical outcome. This study was approved by
the Ethics Committee on Clinical Investigation of Teikyo
University (Tokyo, Japan) and is registered with Clinical
Trials.gov (NCT 00632333). Written informed consent
was obtained from all individuals. The trial was carried
out in accordance with the Helsinki declaration on experi-
mentation on human subjects.
Patients eligibility
The eligibility criteria for patients participating in the
clinical trial were as follows: (1) they were unresectable
ESCC patients with widespread ESCC who refused
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(2) they have disease which is possible the evaluation of
clinical response ( no limitation with respect to the pres-
ence or absence of measurable diseases according to
RECIST ); (3) they were HLA-A*2402-positive patients by
DNA typing of HLA-A genetic variations; (4) no therapy
4 weeks prior to the initiation of the trial; (5) ECOG
performance status was 0-2; (6) their expected survival
was at least 3 months; (7) the age of the patients was
between >20 and <80 years; and (8) adequate bone-
marrow, cardiac, pulmonary, hepatic and renal func-
tions had to be present, including white blood cell
count >2000/mm3, platelet count >75000/mm3, total
bilirubin < 1.5 times of the institutional normal upper
limits, creatinine < 1.5 times of the institutional normal
upper limits, AST/ALT/ALP <2.5 times of the insti-
tutional normal upper limits. The exclusion criteria of
patients participating in the clinical trial were as follows.
(1) pregnancy; (2) breastfeeding; (3) active or uncontrolled
infection; (4) concomitant treatment with steroids or
immunosuppresing agents; (5) other active or uncon-
trolled other malignancy; (6) disease to the central nervous
system; (7) some other form of unsuitableness as deter-
mined by the principal investigator or physician.
Toxicity assessment
Signs of toxicities were assessed by the Common Ter-
minology Criteria for Adverse Event (CTCAE) version
3. Blood count and serum chemistry tests were per-
formed every 2 weeks. The worst toxicity throughout
the treatment period (2 courses of CRT and 8th peptide
vaccination) was investigated. Dose escalation was
performed in 3 patients’ cohort with dose of 0.5 mg,
1 mg and 3 mg for each peptide. Dose-limiting toxicity
(DLT) was defined as a hematological toxicity of grade
4 and non-hematological toxicity of grade 3 or greater.
Peptides
The peptides derived from TTK-567 (SYRNEIAYL),
URLC10-177 (RYCNLEGPPI), KOC1-508 (KTVNELQNL),
VEGFR1-1084 (SYGVLLWEIF), VEGFR2-169 (RFVPDG
NRI) that bound to the HLA-A*24 molecule were synthe-
sized by the American Peptide Company (Sunnyvale, CA,
USA). The purity (>97%) and identify of the peptides were
determined by analytical high-performance liquid chroma-
tography (HPLC) and mass spectrometry analysis, respect-
ively. The endotoxin levels and bioburden of these peptides
were tested and determined to be within acceptable levels
as GMP grade for the vaccines (NeoMPS, Inc.).
Measurement of CTL responses
An enzyme-linked immunospot (ELISPOT) assay was per-
formed to measure the peptide specific CTL response, as
described previously [23,25]. For the evaluation of CTLand Flow cytometry, blood samples were obtained from
the patients at the pre-vaccination period and after the 4th,
8th, 12th and 16th vaccinations. Briefly, peripheral blood
mononuclear cells (PBMCs) of blood samples were
cultured with respective peptide and IL-2 (Novartis,
Emeryville, CA) at 37°C for two weeks. Peptide was
added into the culture at day 0 and day 7. Following
CD4+ cell depletion by Dynal CD4 positive isolation kit
(Invitrogen, Carlsbad, CA), IFN-γ ELISPOT assay was
performed using Human IFN-γ ELISPOT PLUS kit
(MabTech, Nacka Strand, Sweden) according to the
manufacturer’s instructions. The number of peptide
specific spots was calculated by subtracting the spot
number in the control well from the spot number of
wells with peptide-pulsed TISI cells. The positivity of
the antigen-specific T cell responses were classified into
four grades (−, +, ++ and +++), depending on the
peptide-specific spots at different responder/stimulator
ratios. When the algorithm indicated +, ++ or +++, we
judged it to be a positive case.
Flow cytometry
Expression of peptide specific T cell receptors was ana-
lyzed on FACS-CantoII (Becton Dickinson, San Jose,
CA) using URLC10, TTK, KOC1, VEGFR1 or VEGFR2-
derived epitope peptide-MHC dextramer (Immudex,
Copenhagen, Denmark) or tetramer-PE (Medical & Bio-
logical Laboratories Co.,Ltd., Nagoya, Japan) according
to the manufacturer’s instructions. HIV-derived epitope
peptide (RYLRDQQLL)-MHC dextramer or tetramer-PE
was used as a negative control. T cells were incubated with
peptide-MHC dextramer or tetramer-PE, treated with
FITC-conjugated anti-human CD8 mAb, APC-conjugated
anti-human CD3 mAb, PE-Cy7-conjugated anti-human
CD4 mAb, and 7-AAD (BD Pharmingen, San Diego, CA.),
and then analyzed with flow cytometry.
Immunohistchemical
Immunohistochemical (IHC) staining of HLA class I,
TTK, URLC10, KOC1, VEGFR1 and VEGFR2 antigens of
the ESCC and adjacent normal tissues were investigated
using the serial sections of formalin-fixed, paraffin-
embedded biopsy samples, as described previously [25].
The primary antibodies used in this study were as
follows: HLA class I (Cosmo Bio. Co.Ltd. Tokyo, Japan),
URLC10 (Imagenex, San Diego, CA.), TTK (Novus Bio.
LLC. Littleton, CO.), KOC1 (Santacruz Bio. Inc. Dallas,
Texas), VEGFR1 (Novus Bio. LLC.) and VEGFR2 (R&D
Systems Inc., Minneapolis, MN). Immunoreaction was
detected using the following secondary antibody sys-
tems: Simple Stain MAX-PO kit (Nichirei Bioscience,
Tokyo, Japan) for HLA class I, URLC10, KOC1 and
TTK; and CSA-II Biotin-free Tyramide Single Amplifi-
cation System (Dako Inc., Carpinteria, CA) for VEGFR1
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manufacturer. The intensity of staining was evaluated
using the following criteria: strong positive staining of
more than 80% (+++), positive staining of 50-80% (++);
positive less than 50% (+); and no appreciable staining
in tumor cells (−).
Statistical analysis




Between March 2008 and October 2011, 11 unresectable
ESCC patients enrolled in this study. The characteristics
of these patients are shown in Table 1. The patients
comprised 10 males and 1 female, with a median age of
65 years (range 58-71 years). All patients were positive for
HLA-A*2402. Performance status was 0 for 8 patients, 1
for 1 patient and 2 for 2 patients. The stages of ESCC
were: 3 patients with stage II (No 1, 2, 7), 4 patients with
stage III (No.4, 5, 6, 10) and 4 patients with stage IV (No.Table 1 Patients’ characteristics
Patient no. Dose of peptides (mg) HLA Age (Y
1 0.5 A2402 59
2 0.5 A2402 58
3 0.5 A2402 69
4 1.0 A2402 64
5 1.0 A2402 65
6 1.0 A2402 61
7 3.0 A2402 70
8 3.0 A2402 63
9 3.0 A2402 67
10 3.0 A2402 71
11 3.0 A2402 67
*Stage according to the TNM classification for esophageal cancer (UICC).
**PS: Performance status (ECOG).3, 8, 9, 11). These patients were unresectable by reason of
widespread ESCC (No 1, 2, 7), lymph node metastasis (No
2-11), adrenal gland metastasis (No.9) and lung metastasis
(No 11).Adverse events
DLT of our study was evaluated by the dose escalation
schedule. The worst toxicity throughout the treatment
of 2 courses of CRT and 8th vaccination was investi-
gated in each patient (Table 2). This therapy was well-
tolerated without any serious adverse events. Major
toxicities were myelo-suppression and esophagus-
related toxicities. Grade 3 toxicities of leucopenia, neu-
tropenia, anemia and thrombocytopenia occurred in
54.5%, 27.3%, 27.3% and 9.1% of patients, respectively.
Grade 2 toxicities of esophagitis, nausea/vomiting, diar-
rhea, stomatitis/pharyngitis and hypernatremia occurred
in 18.2%, 18.2%, 9.1%, 27.3% and 27.3% of patients,
respectively. Grade 1 local skin reactions in the peptide
vaccine injection sites were observed in 81.8%. DLT of
peptide vaccine was not observed in this trial.) Gender Stage* PS** Target organ
M IIA 0 Primary tumor
M IIB 0 Primary tumor
Lymph node
F IVA 1 Primary tumor
Lymph node
M III 2 Primary tumor
Lymph node
M III 2 Primary tumor
Lymph node
M III 0 Primary tumor
Lymph node
M IIB 0 Primary tumor
Lymph node
M IVA 0 Primary tumor
Lymph node
M IVB 0 Primary tumor
Lymph node
Adrenal gland
M III 0 Primary tumor
Lymph node
M IVB 0 Primary tumor
Lymph node
Lung
Table 2 Summary of adverse events
Toxicity Peptide Total patients (n = 11)
0.5 mg (n = 3) 1.0 mg (n = 3) 3.0 mg (n = 5)
Grade* Grade Grade Grade (%)
1 2 3 1 2 3 1 2 3 1 2 3
Dermatology/skin
Reaction at the injection site 2 0 0 3 0 0 4 0 0 9 (81.8) 0 (0.0) 0 (0.0)
Hematological
Leukocyte 0 0 2 0 0 2 0 1 2 0 (0.0) 1 (9.1) 6 (54.5)
Neutrocyte 0 1 1 0 1 1 0 2 1 0 (0.0) 4 (36.4) 3 (27.3)
Hemoglobin 1 1 1 1 1 1 1 1 1 3 (27.3) 3 (27.3) 3 (27.3)
Platelet 1 0 0 0 0 1 3 0 0 4 (36.4) 0 (0.0) 1 (9.1)
Non-hematological
Esophagitis 0 1 0 2 0 0 2 1 0 4 (36.4) 2 (18.2) 0 (0.0)
AST 1 0 0 1 0 0 0 0 0 2 (18.2) 0 (0.0) 0 (0.0)
ALT 0 0 0 0 0 0 1 0 0 1 (9.1) 0 (0.0) 0 (0.0)
Creatinine 0 0 0 0 0 0 0 0 0 0 (0.0) 0 (0.0) 0 (0.0)
Nausea/vomiting 1 0 0 0 1 0 0 0 0 1 (9.1) 2 (18.2) 0 (0.0)
Diarrhea 0 1 0 0 0 0 0 0 0 0 (0.0) 1 (9.1) 0 (0.0)
Stomatitis/pharyngitis 0 1 0 0 1 0 0 1 0 0 (0.0) 3 (27.3) 0 (0.0)
Hyponatremia 0 2 0 1 0 0 1 1 0 2 (18.2) 3 (27.3) 0 (0.0)
*Adverse events were graded according to the CTCAE v3.0.
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We evaluated the expression levels of HLA Class I,
URLC10, TTK, KOC1, VEGFR1 and VEGFR2 antigens
in biopsy samples of the enrolled patients (Table 3).
HLA class I antigen was strong expressed in cell mem-
brane of tumor cells of all cases. The strong expressionsTable 3 Immunohistochemical staining to each antigen of
ESCC tissues
Patients no. Immunohistochemistry*
HLA class I URLC10 TTK KOC1 VEGFR1 VEGFR2
1 + + + + + + + + + + + + + + +
2 + + + + + + + + + + + + + + + +
3 + + + + + + + + + + + + +
4 + + + + + + + + + + + + + + +
5 + + + + + + + + + + + + + + +
6 + + + + + + + + + + + + + + +
7 + + + + + + + + + + + + + + + +
8 + + + + + + + + + + + + +
9 + + + + + + + + + + + + + + + +
10 + + + + + + + + + + + + + +
11 + + + + + + + + + + + + + + + +
*(+++): strong positive staining of more than 80%.
(++): positive staining of 50-80%, (+): positive less than 50%.
(−): no appreciable staining.of URLC10, TTK and KOC1 antigens were observed in
cytoplasm of tumor cells of all patients. The expressions
of VEGFR1 and VEGFR2 were observed in tumor cells
and stromal vessels of the ESCC tissues of all patients.
Representative IHC staining of these antigens in case 6
is shown in Figure 1. Strong expressions of URLC10,
TTK, KOC1 and MHC class I antigens were observed in
the tumor cells. Expressions of approximately the same
intensity of VEGFR1 and VEGFR2 were observed in the
tumor cells and stromal vessels of the ESCC tissues.
In the adjacent normal esophageal tissues, no staining
of these antigens was observed (data not shown).
Peptide-specific CTL responses
An IFN-γ ELISPOT assay was evaluated using PBMC
periodically obtained from patients to assess the cellular
immune responses to 5 kinds of peptides. Additional file
2: Table S1 shows the CTL responses to each peptide be-
fore and after the 4th, 8th, 12th and 16th vaccination, and
Table 4 shows a summary of the CTL positive rates at
each vaccination point. All patients showed peptide-
specific CTL responses in at least one of the 5 kinds of
peptide antigens during the vaccination. In these pep-
tides, URLC10 showed the highest CTL positive rates.
They were 70.0% at the 4th vaccination point, 54.5% at
the 8th vaccination point, and 100% at the 12th and 16th
vaccination points. CTL positive rates of the other








Figure 1 Immunohistochemical staining of HLA class I, URLC10,
TTK, KOC1, VEGFR1 and VEGFR2 antigens in the ESCC tissues.
Typical expression of HLA class I, URLC10, TTK, KOC1, VEGFR1 and
VEGFR2 in the primary ESCC tissues obtained from case 6 are
shown. The staining was undertaken using the serial sections of
the biopsy sample.
Table 4 Summary of positive rates of CTL responses to each p
Positive rates of CTL responses to each antigen in all patients (n = 11)
Number of vaccination URLC10 (%) TTK (%) KO
Pre-vac. 27.3 (3/11) 36.4 (4/11) 40
4 70.0 (7/10) 27.3 (3/11) 45
8 54.5 (6/11) 36.4 (4/11) 45
12 100.0 (5/5) 40.0 (2/5) 6
16 100.0 (5/5) 40.0 (2/5) 6
CTL positive rates on the pre-vaccination, 4th, 8th, 12th or 16th vaccination were exa
the ELISPOT Assay indicated +, ++ or +++, we judged it to be positive case. *p valu
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45.5-60% for KOC1, 33.3-60% for VEGFR1, and 36.4-
80.0% for VEGFR2, respectively. Furthermore, the average
peptide numbers per patient which induced CTL on 8th
vaccinations were 0.7 in 0.5 mg, 1.3 in 1.0 mg and 3.4 in
3.0 mg peptide administration (Table 5). Three mg of
peptide induced peptide-specific CTLs more effectively
than the 0.5 mg and 1 mg.
Figure 2 shows the representative data from ELISPOT
assays against URLC10 in case 6 at the 8th vaccination
point. URLC10-specific T cell responses were observed
in PBMC derived from patient (Figure 2a, b). Moreover,
the peptide-specific CD8 (+) T cells in the cultured T
cells were confirmed by the flow cytometry, and 6.93%
URLC10 dextramer positive cells were confirmed in the
CD8+CD3+CD4− T cells (Figure 2c).Clinical outcome
The clinical responses at the time of the 8th peptide
vaccination and latest diagnosis points were evaluated
according to the RECIST and are summarized in Table 6.
At the time of the 8th peptide vaccination in combin-
ation with CRT, 6 patients achieved CR (stage II: No. 1,
2, 7; stage III: No.5, 6, 10), and 5 patients revealed PD
(stage III: No. 4; stage IV: No. 3, 8, 9, 11). The CR rates
were 100% (3/3) in stage II, 75% (3/4) in stage III and
0% (0/4) in stage IV. Furthermore, after that, 6 CR
patients were continuously administered the 5 peptide
vaccines, once every 2 weeks for 1 year and once a
month after that until PD. Five of these 6 patients con-
tinued the CR with no evidence of disease for 4.5 years
(No. 1), 4.6 years (No. 2), 2.9 years (No. 6), 2.0 years
(No.7) and 1.1 years (No.10), and are still alive. Five
patients died within 1 year, and 1 patient died within
2 years. Figure 3 shows the representative endoscopic
appearance and computed tomography (CT) scan images
of the primary cancer and CT scan images of the lymph
node in the CR patients (case 6). Complete tumor regres-
sion of the primary tumor site (Figure 3c) and lymph node
(Figure 3d) were observed after the treatment of the 8th
peptide vaccinations with CRT.eptide antigen
C1 (%) VEGFR1 (%) VEGFR2 (%) CMV (%)
.0 (4/10) 20.0 (2/10) 40.0 (4/10) 100.0 (10/10)
.5 (5/11) 33.3 (3/9) 45.5 (5/11) 100.0 (11/11)
.5 (5/11) 45.5 (5/11) 36.4 (4/11) 100.0 (11/11)
0.0 (3/5) 40.0 (2/5) 80.0 (4/5) 100.0 ( 5/ 5)
0.0 (3/5) 60.0 (3/5) 80.0 (4/5) 100.0 ( 5/ 5)
mined in all patients (n = 11), CR patients (n = 6) and PD patients (n = 5). When
es.
Table 5 Number of peptides induced CTL on 8th
vaccination








1 0.5 0 0.7
2 0.5 2
3 0.5 0
4 1.0 1 1.3
5 1.0 1
6 1.0 2





*Average number of peptides per patient which induced.



















(a)   ELISPOT assay
(c)   FACS analysis
Figure 2 Representative immunological monitoring assays detecting
after the 8th vaccination were cultured with URLC10-peptide stimulation and
analyzed by flow cytometry, and proportion of URLC10 dextramer positive ce
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Our phase I clinical trial comprising a combination ther-
apy of multiple-peptide vaccine and CRT in patients with
HLA-A*2402 positive unresectable ESCC proceeded with
satisfactory safety levels in all the patients. Peptide-specific
CTL could be induced by the all peptide vaccine. In the
assessment of clinical response, 6 CR and 5 PD cases were
recognized, and 4 CR patients showed a prolonged
survival period for 2.0-4.6 years.
The immunotherapies for unresectable or advanced
ESCC patients using the peptide vaccines are of interest.
Using the NY-ESO-1 peptide mixed with Picibanil OK432
and montanide ISA-51, it has been demonstrated that this
peptide vaccine is able to elicite a CD4 and CD8 T cell
response [26]. The usefulness of peptide vaccines TTK
and URLC10 (LY6K), and KOC1 (IMP-3) have also been
investigated and antigen-specific CD8 T cell responses
successfully elicited in other studies [22,27]. However,
the effects of these studies were limited in their clinical
benefit.
In this study, we hypothesized that immunotherapy
may achieve effective clearance of residual cancer cells
















(b)  ELISPOT assay
peptide-specific CTL response. PBLs obtained from CR patient (case 6)
subjected to the ELISPOT assay (a, b). The cultured lymphocytes were
lls in CD8+CD3+CD4− cells were calculated (c).
Table 6 Clinical responses




PFS (days) OS (days) Outcome
8th vac. Final results
1 IIA CR CR 22 4.5 1659 1775 Alive
2 IIB CR CR 85 4.6 1681 1709 Alive
3 IVA PD PD 8 67 154 Dead
4 III PD PD 8 84 123 Dead
5 III CR PD 12 127 765 Dead
6 III CR CR 69 2.9 1072 1234 Alive
7 IIB CR PD 26 2.0 733 1105 Alive
8 IVB PD PD 10 176 231 Dead
9 IVB PD PD 8 59 300 Dead
10 III CR CR 36 1.1 384 660 Alive
11 IVB PD PD 15 155 217 Dead
*Clinical responses of patients were analyzed after the 8th vaccination and the latest diagnosis points. CR: complete response; PD: progressive disease; PFS:
Progression-free survival; OS: overall survival.
(a) Original site :
Pre-treatment
(b) Original site :
Post- treatment (8th vaccination) 
(c) Lymph node metastasis :    
Pre-treatment
(d)  Lymph node metastasis:
Post- treatment  (8th vaccination)
Figure 3 Computed tomography (CT) and endoscopic images of CR patient (case 6). The CT and endoscopic images of the original site
(a, b) and CT images of lymph nodes metastasis (c, d) in case 6, before (a, c) and after treatment by CRT with 8th vaccination (b, d) are shown.
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tumor reduction after irradiation is direct damage to
tumor DNA by ionizing irradiation. Recently, however,
several interesting studies have reported that local irradi-
ation of tumor tissue elicits immunomodulation effects
and inhibits tumor growth through the generation of
tumor-specific CTL [28]. This concept has been sup-
ported by the accumulating data of many investigators
based on basic and clinical studies [10-14,29]. Lugade
et al. reported that local radiation increased both the
generation of the peptide-reactive IFN-γ producing
anti-tumor immune cells and their trafficking to the
tumor-draining lymph nodes [10]. The essential role of
CD8+ T-cells in radiation therapy has been demon-
strated and it has been suggested that TLR4 on host
dendritic cells may be crucial role for induction of these
antitumor T cells [11,13,29]. Interestingly, Aktsu et al.
demonstrated that radiation itself not only kills the
tumor cells but can also evoke a systemic antitumor
effect (abscopal effect) by the enhancement of the heat
shock protein gp96 [30]. Furthermore, many studies sup-
port the immunomodulation effects of chemotherapy.
Hattori et al. demonstrated an increase of immunological
responses in cases of personalized peptide vaccination
combined with UFT and UZEL in metastatic colorectal
cancer patients and Sato et al. reported on the useful-
ness of the personalized peptide vaccine in combination
with TS-1 [31,32]. These results suggest that not only
radiation but also some kind of anticancer drug may
have potential could enhance the anti-tumor response
of immunotherapy.
In contrast, clinical trials of immunotherapy com-
bined with CRT have been few in number. Marten et al.
evaluated a randomized phase II trial of adjuvant ther-
apy of IFN-α combined with 5-FU/CDDP and radiation
in patients with R0 or R1 pancreatic adenocarcinoma,
and concluded that this therapy had a minor impact on
the clinical response and the lowering of toxicity levels
[33]. However, no study has hitherto reported a clinical
trial of peptide vaccine combined with CRT in ESCC
patients.
In preliminary examination, we investigated the ad-
verse events of CRT standard regimens in Japan, with a
focus on the number of lymphocytes which is the key
of immunological response of tumor vaccine. Because
JCOG9906 showed the less grade of lymphopenia as
compared with that of other regimen, we selected this
regimen for our study (Additional file 3: Table S2). In
our clinical trial, we have demonstrated that our proto-
col was well-tolerated. Major toxicities were myelo-
suppression and esophagitis may be related to CRT, and
grade 3 toxicities of leucopenia, neutropenia, anemia
and thrombocutopenia occurred in 54.5%, 27.3%, 27.3%
and 9.1% of patients, respectively. With regards to thetoxicities of unresectable advanced ESCC patients treated
with CRT, it was reported that grade 3 leukopenia, neutro-
penia, anemia and esophagitis were observed in 33.3%,
8.3%, 6.7% and 3.3% of the patients, respectively, and
grade 4 platelet, dyspnea and infection were observed in
3.3%, 1.7%, and 1.7% of the patients, respectively [8]. In
contrast to these studies, our protocol did not show any
grade 4 hematological toxicity and non-hematological
toxicity. As toxicity related to peptide vaccine, grade 1
local skin reactions at the injection sites of peptide vac-
cines were observed in 81.8% of patients, which is almost
the same results with that of previous study of peptide
vaccines for ESCC patients [25].
In the guidance of FDA for cancer vaccine, it states
that the maximum tolerated dose for a cancer vaccine
may not be identified except in very rare situations.
Furthermore it was also described that, when no DLT
is expected or achieved, optimization of other out-
comes, such as the immune response, can be useful to
identify doses for subsequent studies [34]. In our
study, DLT was not detected in any patients. However,
in a comparison of the CTL induction of 8th vaccin-
ation, we observed that the 3 mg of peptide seems to
induce peptide-specific CTLs more effectively than the
0.5 mg and 1 mg levels. Therefore, we recommend
that 3 mg be the basis for future study.
In this study, all biopsy samples of ESCC tissues col-
lected from patients showed clear expressions of HLA
class I antigen and all peptides antigens (URLC10, TTK,
KOC1, VEGFR1, and VEGFR2). Positive rates of peptide
specific CTL reactions at the 8th vaccination were 54.5%
for URLC10, 36.4% for TTK, 45.5% for KOC1, 45.5% for
VEGFR1 and 36.4% for VEGFR2, and then increased to
40-100% at the 16th vaccination. CTL positive levels for
URLC10, TTK and KOC1 are almost the same as those
found in previous reports which used the peptide vac-
cine in ESCC patients [22,23]. Regarding the mechan-
ism of CTL production, we speculate that the apoptosis
and necrosis of cancer cells by CRT may induce a pro-
inflammatory response in the tumor environment, and
may enhance the immunogenicity of the cancer cells
and antigen presentation of DC, and that this may result
in increased CTL production (Figure 4).
The clinical responses in our study were 6 CR (3 pa-
tients with stage II, 3 patients with stage III) and 5 PD
(1 patient with stage III, 4 patients with stage IV). It has
been reported that CRT itself showed CR at a rate of
62% (78% in the T1-2 disease and 55% in the T3 disease)
[7]. However, it is known that 30-50% of patients treated
with CRT recur within 1 year [4,5]. In contrast, our
study showed that in 4 cases out of 6 CR patients
showed a long and continuous CR period (2.0-4.6 years).
This study is a phase I trial and the primary endpoint











Figure 4 Mechanism of peptide vaccine therapy combined with CRT.
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peptide vaccines as a comparison group. Therefore, it is
difficult to clarify the clinical significance of these pro-
longed CR periods, at this stage. We expect that anti-
tumor effect of peptide vaccine for residual cancer cells
after CRT will become apparent in phase II trials.Conclusions
To the best of our knowledge our study is the first cli-
nical trial of a multi-peptide vaccine combined with
CRT that has demonstrated the safety and induction of
peptide specific CTL followed by a long CR period in
unresectable ESCC patients. Our results point to the
need to move forward to the next-stage of this combi-
nation therapy in an adjuvant setting of ESCC patients.Additional files
Additional file 1: Figure S1. Treatment protocol.
Additional file 2: Table S1. Peptide antigen-specific CTL responses in
PBLs evaluated by ELISPOT assay.
Additional file 3: Table S2. Comparison of toxicities in two regimens
of CRT.Abbreviations
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VEGFR1: Vascular endothelial growth factor receptor 1; VEGFR2: Vascular
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